|Description||Adipiplon is GABAA receptor partial agonist. It can bind to the α3 subtype. Adipiplon is one of the first drugs selected for clinical development which is able to discriminate between α2 and α3, as well as showing little affinity for the α1 or α5 subtypes .Adipiplon is being researched as a potential medication for the treatment of anxiety and insomnia, and in 2008 it was being used in Phase IIb trials. But these trials were suspended after next-day side effects were discovered.|
|Solubility||Soluble in DMSO|
|Application||anxiety and insomnia|
|Quality Standard||In-house standard|
|Shelf Life||2 month in rt, long time|
|Current Developer||Ligand Pharmaceuticals|
L-655,708, an inverse agonist of α5 subunit involved in GABAA receptor, has been found to exhibit cognitive performance improvement in biological studies.
AWD 131-138 is a partial agonist of GABAA receptor with low affinity for the benzodiazepine binding site. AWD 131-138 exhibits potent anticonvulsant and anxioly...
MRK-016 is a selective α5 subunit-containing GABAA negative allosteric modulator with EC50 value of 3 nM. It has nootropic properties. MRK-016 can produce rapid...
BHFF is a positive allosteric modulator of GABAB receptor that increases the potency and efficacy of GABA. BHFF displays anxiolytic activity in vivo.
PHP 501 trifluoroacetate
PHP 501 trifluoroacetate is potent GABAA antagonist (Ki = 0.0028 μM at rat GABAA receptors; IC50 = 0.024 μM at human α1β2γ2 GABAA-expressing tsA201 cells), with...
Etifoxine, also called as HOE 36801 or Stresam, is a positive allosteric modulator of GABAreceptors that produces anxiolytic effects by preferentially modulatin...
Ro 15-4513, a high affinity benzodiazepine ligand, acts as a competitive antagonist, and can therefore be an antidote to the acute impairment caused by alcohol....
CH-50911 is a selective GABA-B antagonist with IC50 value of 1.1 μM. It is developed by Schering-Plough Corporation. CH-50911 is often used in pharmacology rese...